Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates: A Prospective Randomized Trial

What this Trial Is About

Benign prostatic hyperplasia (BPH) is a common condition in men that often requires surgical treatment as it progresses. This trial compares two surgical methods, aquablation and Holmium enucleation of the prostate (HoLEP), to see if aquablation is at least as effective and safe as HoLEP for treating medium to large prostate sizes. The study aims to support the use of aquablation, which may have advantages in learning curve and operation time, potentially changing clinical practice. Aquablation uses a robotic high-pressure water jet guided by real-time ultrasound imaging to remove prostate tissue without heat. HoLEP involves using a laser to remove prostate tissue endoscopically under general anesthesia. Both procedures include catheter placement and bladder irrigation after surgery. Participants will be randomly assigned to receive either aquablation or HoLEP. Participants will be men aged 45 or older with medium to large prostates who meet specific urinary symptom and flow criteria. Researchers will assess outcomes such as symptom scores using the International Prostate Symptoms Score (IPSS) at 6 months. The study includes monitoring for safety and functional results to compare both treatments' effects on urinary symptoms and quality of life.

Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates